NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading KURA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Recognize $45M to $55M in non-cash collaboration revenue in 2026: collaboration revenue $45M to $55M vs target $45M+.
View ThesisManagement screens weak on capital allocation, earnings delivery.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 39% in its worst 12-month stretch.
View RiskKURA needs to improve its performance to justify its current price. The company has been unprofitable over the past year. Its recent financial performance has been steady but below industry peers. KURA trades at 11.5× price-to-sales, above the peer median of 8.7×. This premium suggests the market expects better growth. A specific risk is the 48% chance of missing earnings guidance next quarter. Peer multiples imply a price about 51% above where it trades. This read is provisional.
Trailing returns as of 2026-07-31. KURA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering KURA (as of Jul 2026).
Based on 6 Wall Street analysts offering 12-month price targets for KURA in the last 4 months.
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Broaden ziftomenib opportunity
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $9.01
The last 12 months of price, then the range of analyst 12-month targets from today’s $9.01.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Long-term results support ziftomenib's potential in AML.
Advances: Broaden ziftomenib opportunity
Updated strategy enhances growth prospects for ziftomenib.
Advances: Broaden ziftomenib opportunity
Phase 1a data shows promise for cancer drug combinations.
Advances: Broaden ziftomenib opportunity
Tumor shrinkage indicates effectiveness of drug trial.
